# US 10,500,189 B2 · Composition comprising a diindolylmethane and a retinoid to treat a skin condition > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,500,189 B2 - Document ID: US10500189B2 - Status: Granted - Kind: B2 - Application number: 15/881,453 - Filed: 2018-01-26 - Published: 2019-01-03 - Granted: 2019-12-10 - Earliest claimed: 2011-03-25 - Assignees: Skintech Life Sciences Limited - Applicants: Skintech Life Science Limited - Inventors: David Alpert - Web page: https://patentgrep.com/patent/US10500189B2 ## CPC - A61K 31/404: Indoles, e.g. pindolol - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203) - A61K 31/203: Retinoic acids {; Salts thereof} - A61K 31/215: of carboxylic acids - A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate - A61K 31/22: of acyclic acids, e.g. pravastatin - A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms - A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine - A61K 31/566: having an oxo group in position 17, e.g. estrone - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 17/00: Drugs for dermatological disorders - A61P 17/08: Antiseborrheics - A61P 17/10: Anti-acne agents - A61P 17/16: Emollients or protectives, e.g. against radiation - A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00) - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Provided is a composition for use in treating a skin condition, the composition comprising: (a) a first component comprising a substituted or unsubstituted diindolylmethane compound; and (b) a second component comprising a substituted or unsubstituted retinoid compound. ## Claims ### Claim 1 A dosage form comprising a first component and a second component, wherein: a. the first component is a 3-3′ diindolylmethane compound comprising the following formula: and b. the second component is a first generation retinoid, a second generation retinoid, or a third generation retinoid, wherein the dosage form comprises at least 10 mg of the first component and at least 50 μg of the second component. ### Claim 2 (depends on 1) The dosage form of claim 1, wherein the ratio (mg:μg) of the first and the second component is from about 10:3000 to about 500:200. ### Claim 3 (depends on 1) The dosage form of claim 1, wherein the ratio (mg:μg) of the first and the second component is from about 75:800 to about 300:200. ### Claim 4 (depends on 1) The dosage form of claim 1, wherein the ratio (mg:IU) of the first and the second component is from about 75:10000 to about 300:2500. ### Claim 5 (depends on 1) The dosage form of claim 1, wherein the ratio (mg:mg) of the first and the second component is from about 75:5.3 to about 300:1.3. ### Claim 6 (depends on 1) The dosage form of claim 1, wherein the dosage form comprises a first capsule comprising the first component and a second capsule comprising the second component. ### Claim 7 (depends on 1) The dosage form of claim 1, wherein the dosage form comprises a capsule comprising the first component and the second component, wherein the first and the second component are provided in a single formulation. ### Claim 8 (depends on 7) The dosage form of claim 7, wherein the single formulation comprises a blended powder comprising the first and the second component. ### Claim 9 (depends on 1) The dosage form of claim 1, wherein the dosage form comprises a first tablet comprising the first component and a second tablet comprising the second component. ### Claim 10 (depends on 1) The dosage form of claim 1, wherein the dosage form comprises a tablet comprising the first component and the second component, wherein the first and the second component are provided in a single formulation. ### Claim 11 (depends on 1) The dosage form of claim 1, wherein the first component is in a microencapsulated form. ### Claim 12 (depends on 1) The dosage form of claim 1, further comprising at least one excipient selected from the group consisting of: tricalcium phosphate, cellulose fiber, ascorbic acid, silicon dioxide, magnesium stearate, and any combination thereof. ### Claim 13 (depends on 1) The dosage form of claim 1, wherein a daily dose of the dosage form comprises at least one capsule or tablet comprising the first component and at least one capsule or tablet comprising the second component. ### Claim 14 (depends on 1) The dosage form of claim 1, wherein a daily dose of the dosage form comprises at least one capsule or tablet comprising the first component and the second component, wherein the first and the second component are provided in a single formulation. ### Claim 15 (depends on 1) The dosage form of claim 1, wherein the dosage form comprises a single capsule comprising about 75 mg of the first component and about 200 μg of the second component. ### Claim 16 (depends on 1) The dosage form of claim 1, wherein the dosage form comprises a single capsule comprising the first component and the second component, and wherein the single capsule comprises an opaque capsule. ### Claim 17 (depends on 1) The dosage form of claim 1, wherein the dosage form comprises a gel. ### Claim 18 (depends on 1) The dosage form of claim 1, wherein the retinoid compound comprises the first generation retinoid compound, and wherein the first generation retinoid compound comprises retinyl palmitate. ### Claim 19 A composition comprising a first component, a second component, and a third component, wherein: a. the first component is a diindolylmethane compound comprising a formula selected from: and b. the second component is a first generation retinoid, a second generation retinoid, or a third generation retinoid; and c. the third component is an antibiotic compound, a nutraceutical compound, a contraceptive, or any combination thereof. ### Claim 20 (depends on 19) The composition of claim 19, further comprising an additional component selected from the group consisting of: a vitamin, a mineral, sulphur or a sulphur containing compound, a resorcinol compound, an azelaic acid compound, a salicylic acid compound, a plant product, and any combination thereof.